An observational study in Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Heart Failure, sponsored by West China Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by West China Hospital · Observational
The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.
Hyperdynamic circulation is a common Phenomenon in cirrhosis due to systemic and splanchnic vasodilatation, which may result cardic dysfunction and abnormal structure ,called cirrhotic cardiomyopathy(CCM). Transjugular intrahepatic portosystemic shunt (TIPS), as a effective technique to alleviates portal hypertension in cirrhotic patients, often be used to treat with refractory ascites and variceal bleeding which endoscopy and drug therapy are ineffective. However, owing to the increased shunting of blood from the splanchnic vascular bed into the central vascular bed, TIPS further exacerbates the hyperdynamic circulatory state, which may lead to heart failure.yet there are no convincing research to study the incidence of heart failure in cirrhosis after transjugular intrahepatic portosystemic shunt. The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.
1,668 studies on the registry are indexed under Liver Cirrhosis; 360 are open to participants now.
This study's planned enrollment of 200 is above the median of 152 across 605 observational studies indexed under Liver Cirrhosis.
Browse Liver Cirrhosis studies →West China Hospital is the lead sponsor of 497 studies on the registry; 243 are open to participants now.
Counted across the registry records on this site, refreshed daily.
cirrhotic patients undergoing TIPS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with cirrhosis who underwent TIPS due to complications of portal hypertension were inclueded for observation.
Procedure: TIPS
TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
Incidence of heart failue
Heart failue assessed by2021 ESC Guidelines
Time frame: up to 36 months
Predictors of heart Failure
Heart failue assessed by2021 ESC Guidelines
Time frame: up to 36 months
mortality
Telephone follow-up was performed to collect relevant information
Time frame: up to 36 months
Modififications of cardiac function
Echocardiography was to evaluate cardic function
Time frame: up to 36 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.